Trial record 11 of 23 for:    Open Studies | "Vulvar Neoplasms"

The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence (WOMAN-PROII)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by St.Gallen University of Applied Sciences
Sponsor:
Collaborators:
University Hospital Inselspital, Berne
University Hospital, Zürich
University Hospital, Basel, Switzerland
Cantonal Hospital of St. Gallen
Medical University of Vienna
Royal Prince Alfred Hospital, Sydney, Australia
Information provided by (Responsible Party):
St.Gallen University of Applied Sciences
ClinicalTrials.gov Identifier:
NCT01986725
First received: May 21, 2013
Last updated: November 11, 2013
Last verified: November 2013
  Purpose

In vulvar neoplasia, even minor surgical interventions cause multiple symptoms, symptom distress and complications, which have an impact on a woman's quality of life and contribute to high health care costs. For the majority of the patients, symptom and distress can be reduced if adequate treatment is provided. This study aims to test possible differences between the impact of standardized care and the WOMAN-PRO II program on symptom prevalence in women with vulvar neoplasia after surgical treatment.

In a sequential explanatory mixed-methods project, a randomized phase II study will be followed by a qualitative sub-study. Ninety patients with vulvar neoplasia treated surgically will participate in the randomized trial in four Swiss hospitals, one Austrian and one Australian hospital. After stratification by precancer/cancer, women will be randomly assigned (1:2 ratio) to standardized care and the WOMAN-PRO II program. The standardized care group will receive a set of information leaflets about supportive care options in the clinic. The WOMAN-PRO II program group will obtain counseling sessions by specially trained gynecology-oncology nurse specialists at the moment of diagnosis, 7 days post-surgery, in week two after discharge, week twelve and week 24 after surgery. The primary outcome of this study is symptom prevalence. Secondary outcomes will be collected for explorative reasons and include symptom distress, uncertainty, quality of life, social support, resilience, quality of care, sociodemographic and medical characteristics, post-surgical complications, functional status, cost evaluation and process outcomes. Quantitative data will be collected at the counseling points of time and analyzed by using mixed linear regression analysis. Twenty interviews will be conducted with women of the WOMAN-PRO II program group. A focus-group interview will be conducted with twelve gynecology-oncology nurse specialists in order to better understand to which degree the interventions meet individual needs as well as to identify remaining barriers and enablers for the implementation of symptom self-management. Qualitative data will be analyzed by using thematic analysis and a critical hermeneutic reflection.

This study will evaluate the impact of the WOMAN-PRO II program on symptom prevalence, patient-reported outcomes and clinical parameters, and inform the design of a possible phase III study on the clinical efficacy of the program. 


Condition Intervention Phase
Vulvar Cancer
Vulvar Intraepithelial Neoplasia
Behavioral: standardized care (Intervention I)
Behavioral: Standardized care + WOMAN-PRO II program (Intervention II)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Supportive Care
Official Title: The Impact of the Self-management Intervention "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence: A Mixed-Methods Project

Resource links provided by NLM:


Further study details as provided by St.Gallen University of Applied Sciences:

Primary Outcome Measures:
  • Changes in symptom prevalence [ Time Frame: Change from baseline symptom prevalence at 6 months, measured on the following points of time: diagnosis, 7 days post-surgery, week two after discharge, week twelve and week 24 after surgery ] [ Designated as safety issue: No ]
    The primary endpoint of the quantitative study is symptom prevalence, defined as a number of occurring symptoms on predefined time points from diagnosis (t0) across repeated measurements to follow-up assessment at six months after surgery (t4) Symptom prevalence after surgical treatment of vulvar neoplasia will be measured with the German WOMAN-PRO symptom diary. This self-report patient-reported outcome measure covers 31 symptoms occurring after surgery: 15 wound-related symptoms, 5 difficulties in daily life and 11 items that inquire about psychosocial feelings, thoughts or activities. For wound-related symptoms and difficulties in daily life, women are asked to rate how frequently they experienced the symptom/difficulty during the last seven days (never, for 1-2 days, 3-4 days, or 5-7 days).


Secondary Outcome Measures:
  • Changes in symptom severity [ Time Frame: Change from baseline symptom severity at 6 months. ] [ Designated as safety issue: No ]
    Symptom severity after surgical treatment of vulvar neoplasia will also be measured with the WOMAN-PRO symptom diary. This self-report patient-reported outcome measure covers 31 symptoms occurring after surgery: 15 wound-related symptoms, 5 difficulties in daily life and 11 items that inquire about psychosocial feelings, thoughts or activities. For the psychosocial symptoms/issues, women are asked to assess the severity of symptoms (not at all, a little bit, quite a bit, very much).

  • Changes in Uncertainty-Mishel Uncertainty in Illness Scale (MUIS) [ Time Frame: Change from baseline uncertainty at 6 months. ] [ Designated as safety issue: No ]
    The Mishel Uncertainty in Illness Scale (MUIS) is a 30-item scale detecting uncertainty in symptomatology, diagnosis, treatment, relationship with care-givers, and planning for the future.

  • Changes in the Health-related quality of life [ Time Frame: Change from baseline health-related quality of life at 6 months ] [ Designated as safety issue: No ]
    The validated German and English Short Form (SF-36) will be administered. It utilizes scale profile, 36 questions and a one-week recall period. It contains eight subscale scores: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Items are rated on a 3-6-point Likert scale.

  • Changes in the perceived social support [ Time Frame: change form baseline perceived social support at 6 months ] [ Designated as safety issue: No ]
    The Multidimensional Scale of Perceived Social Support (MSPSS) is a 12-item scale designed to assess three aspects of perceived social support. The tree aspects comprise support from friends, family, and significant others.

  • Changes in Resilience [ Time Frame: Change from baseline reslilience at 6 months ] [ Designated as safety issue: No ]
    Resilience refers to positive adaptation following stress or trauma. The original Connor-Davidson Resilience Scale brief version (CD-RISC 10) is a 10-item scale assessing resilience during the last month, with higher scores indicating higher resilience capacity.

  • Changes in Patient Assessment of Chronic Illness Care [ Time Frame: change from baseline Patient Assessment of Chronic Illness Care at 6 months ] [ Designated as safety issue: No ]
    The Patient Assessment of Chronic Illness Care (PACIC) instrument evaluates the quality and patient-centeredness of chronic illness care based on the Chronic Care Model (CCM)

  • Socio-demographic outcomes [ Time Frame: baseline ] [ Designated as safety issue: No ]
    Socio-demographic outcomes for patients will be collected with an 11-items form concerning age, marital status, number of children, education, employment status, living situation, post surgical wound management at home, and health insurance. The instrument was developed for patients following vulvar surgical treatment.

  • Changes in clinical outcomes [ Time Frame: change from baseline clinical outcomes at 6 months ] [ Designated as safety issue: No ]
    Clinical outcomes for patients will be collected with a 16-items form concerning diagnosis, cancer stage, initial treatment, and wound treatment. The instrument was developed for patients following vulvar surgical treatment.

  • Changes in functional status [ Time Frame: Change from baseline functional status at 6 months. ] [ Designated as safety issue: No ]
    The functional status, referring to the capacity to perform a variety of activities that are normal for most people, will be measured with the Eastern Cooperative Oncology Group Performance Status (ECOG-PS). ECOG-PS is a one item five-point scale using verbal descriptors, ranging from 0 "fully active" to 5 "dead". It was developed in 1960 for cancer patients and has been widely used by physicians and researchers to assess how a patient's disease is progressing and how it affects the daily living abilities.

  • Changes in Assessment of Chronic Illness Care [ Time Frame: Change from baseline assessment of chronic illness care at 6 months. ] [ Designated as safety issue: No ]
    The Assessment of Chronic Illness Care (ACIC) questionnaire was developed to assess if provided care is in alignment with the Chronic Care Model (CCM). The CCM comprises six areas: the organization of the health care system, the community linkage, self-management, decision support, delivery system design, and the clinical information system. The ACIC adresses how well a practice team or organization integrates the Chronic Care Model elements. Responses can be related to four descriptive levels from A "fully implemented" to D "little or none" implementation of the intervention.

  • Process outcomes [ Time Frame: 6 months (baseline - 24 weeks following surgery) ] [ Designated as safety issue: No ]
    The collection of three process outcomes during the implementation of a complex intervention program will allow to draw conclusions about potential barriers and facilitators of the interaction between patient and gynecology-oncology nurse specialist during the counseling intervention. (1) Counseling competencies and details of the complex interaction between patients and the gynecology-oncology nurse specialist will be assessed during the study period by audio-recording a random sample of 15-20 counseling sessions.(2) The gynecology-oncology nurse will document her experiences after each counseling session by keeping a diary to reveal her personal situation during the counseling process. (3) The WOMAN-PRO II programm teacher will contact the gynecology-oncology nurse specialists every eight weeks and document the content of the discussions by keeping a diary after each contact.

  • economic evaluation [ Time Frame: 6 months (baseline - 24 weeks following surgery) ] [ Designated as safety issue: No ]
    Economic evaluation methods will be performed according to the recommendations of the NICE Reference Case. The economic evaluation will consist of a within-trial analysis and will compare direct costs and six-month outcomes of patients randomized to intervention II versus intervention I. Direct hospital costs will be the primary perspective. The study will record length of hospital stay, primary surgery costs, readmission, costs concerning intervention I, costs concerning intervention II, follow-up costs, patients non-productive time, and mortality. Comparison will be made between baseline and follow-up to estimate incremental cost-effectiveness ratio (ICER) comparing intervention II group with intervention I group in terms of the primary outcome measure (symptom prevalence) and costs.


Estimated Enrollment: 90
Study Start Date: September 2013
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standardized care
During treatment and routine follow-up consultations, patients randomized to standardized care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.
Behavioral: standardized care (Intervention I)
During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
Active Comparator: Standardized care + WOMAN-PRO II program
During treatment and routine follow-up consultations, patients randomized to standardized care + WOMAN-PRO II program will be provided with usual care and nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments.
Behavioral: Standardized care + WOMAN-PRO II program (Intervention II)
This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of vulvar intraepithelial neoplasia (VIN) or vulvar cancer (primary diagnosis or recurrent neoplasia)
  • Surgical treatment of VIN or vulvar cancer in one of the designated hospitals
  • Age > 18

Exclusion Criteria:

  • Patients being judged by a physician or by a gynecology-oncology nurse specialist as not being capable to participate in the trial and to complete the questionnaire due to cognitive, linguistic, emotionally or physically reasons.
  • Patients in concurrently psychiatric treatment
  • Terminal illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01986725

Contacts
Contact: Beate Senn, PhD, RN 0041 71 226 15 25 beate.senn@fhsg.ch
Contact: Dinah Gafner, MScN 0041 31 632 12 10 dinah.gafner@insel.ch

Locations
Switzerland
Institute for Applied Nursing Sciences IPW, University of Applied Sciences FHS St. Gallen, Switzerland Recruiting
St. Gallen, Switzerland, 9001
Contact: Dinah Gafner, MScN, RN    0041 31 632 12 10    dinah.gafner@insel.ch   
Contact: Beate Senn, PhD, RN    0041 71 226 15 25    beate.senn@fhsg.ch   
Principal Investigator: Beate Senn, PhD, RN         
Sub-Investigator: Dinah Gafner, MScN, RN         
Sub-Investigator: Silvia Raphaelis, Mag., RN         
Sub-Investigator: Manuela Eicher, PhD, RN         
Sub-Investigator: Gabriele Meyer, PhD, RN         
Sub-Investigator: Kate White, PhD, RN         
Sub-Investigator: Michael D. Mueller, Dr. med         
Sponsors and Collaborators
St.Gallen University of Applied Sciences
University Hospital Inselspital, Berne
University Hospital, Zürich
University Hospital, Basel, Switzerland
Cantonal Hospital of St. Gallen
Medical University of Vienna
Royal Prince Alfred Hospital, Sydney, Australia
Investigators
Principal Investigator: Beate Senn, PhD, RN Institute for Applied Nursing Sciences IPW, University of Applied Sciences FHS St. Gallen, Switzerland
  More Information

Publications:

Responsible Party: St.Gallen University of Applied Sciences
ClinicalTrials.gov Identifier: NCT01986725     History of Changes
Other Study ID Numbers: WOMAN-PRO II program
Study First Received: May 21, 2013
Last Updated: November 11, 2013
Health Authority: Switzerland: Ethikkommission

Keywords provided by St.Gallen University of Applied Sciences:
vulvar neoplasia
vulvar cancer
vulvar intraepithelial neoplasia
self management
symptom management

Additional relevant MeSH terms:
Vulvar Neoplasms
Neoplasms
Carcinoma in Situ
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Vulvar Diseases
Genital Diseases, Female
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on July 22, 2014